Epilepsy later in life: Managing the unique problems of seizures in the elderly

Geriatrics

Volumn 60, Issue 5 SUPPL., 2005, Pages 3-20

  Rowan, A James ^a   Kelly, Kevin M ^a   Birnbaum, Angela K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CLOZAPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HALOPERIDOL; IMIPENEM; LAMOTRIGINE; LIDOCAINE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PENICILLIN DERIVATIVE; PETHIDINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; THEOPHYLLINE; THYROID HORMONE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; WARFARIN; ZONISAMIDE;

AGED; AGING; CALCIUM TRANSPORT; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC ERROR; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG METABOLISM; EPILEPSY; GAIT DISORDER; HUMAN; HYPONATREMIA; NEUROANATOMY; NEUROPHYSIOLOGY; NURSING HOME; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL ASPECT;

EID: 18444388029     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Butler RN. Aging: the challenge of twenty-first century medicine. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston, Mass: Butterworth-Heinemann; 1997:3-5.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34:453-468.
3. Hauser WA. Seizure disorders: the changes with age. Epilepsia. 1992;33 (suppl 4):S6-S14.
4. Hauser WA. Epidemiology of seizures and epilepsy in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston, Mass: Butterworth-Heinemann; 1997:7-18.
5. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41:965-972.
6. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci. 2000;55:M384-M392.
7. Sullivan EV, Rosenbloom M, Serventl KL, Pfefferbaum A. Effects of age and sex on volumes of the thalamus, pons, and cortex. Neurobiol Aging. 2004;25:185-192.
8. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci. 2003;23:3295-3301.
9. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science. 1997;278:412-419.
10. Pakkenberg B, Gundersen HJ. Neocortical neuron number in humans: effect of sex and age. J Comp Neurol. 1997;384:312-320.
11. Long JM, Mouton PR, Jucker M, Ingram DK. What counts in brain aging? Design-based stereological analysis of cell number. J Gerontol A Biol Sci Med Sci. 1999;54:B407-B417.
12. Turlejski K, Djavadian R. Life-long stability of neurons: a century of research on neurogenesis, neuronal death and neuron quantification in adult CNS. Prog Brain Res. 2002;136:39-65.
13. Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol. 2003;69:143-179.
14. Shen J, Barnes CA. Age-related decrease in cholinergic synaptic transmission in three hippocampal subfields. Neurobiol Aging. 1996:17:439-451.
15. Barnes CA, Rao G, McNaughton BL. Increased electrotonic coupling in aged rat hippocampus: a possible mechanism for cellular excitability changes. J Comp Neurol. 1987;259:549-558.
16. Barnes CA. Long-term potentiation and the ageing brain. Philos Trans R Soc Lond B Biol Sci. 2003;358:765-772.
17. Landfield PW. 'Increased calcium-current' hypothesis of brain aging. Neurobiol Aging. 1987;8:346-347.
18. Kelly KM, Nadon N, Morrison J, Thibault O, Barnes CA, Blalock E. The neurobiology of aging. Epilepsy Res. 2004. In press.
19. Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. Science. 1996;272:1017-1020.
20. Kelly KM, Kume A, Albin RL, Macdonald RL. Autoradiography of L-type and N-type calcium channels in aged rat hippocampus, entorhinal cortex, and neocortex. Neurobiol Aging. 2001;22:17-23.
21. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther. 1986;238:727-738.
22. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S9-S17.
23. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(suppl 5):S2-S10.
24. Macdonald RL, Rogers CJ, Twyman RE. Kinetic properties of the GABAA receptor main conductance state of mouse spinal cord neurones in culture. J Physiol. 1989;410:479-499.
25. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol. 1994;35:229-234.
26. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989;25:582-593.
27. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861-9866.
28. Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet. 1990;336:1267-1271.
29. Hauser WA, Anderson VE, Loewenson RB, McRoberts SM. Seizure recurrence after a first unprovoked seizure. N Engl J Med. 1982;307:522-528.
30. Shinnar S, Berg AT, Moshe SL, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study. Pediatrics. 1990;85:1076-1085.
31. Wannamaker BB, Booker HE. Treatment of provoked seizures. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 2. Philadelphia, Pa: Lippincott-Raven; 1997:1311-1316.
32. Porter RJ, Mattson RH. Alcohol and drug abuse. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 3. Philadelphia, Pa: Lippincott-Raven; 1997:2629-2633.
33. Wolf P. International Classification of the Epilepsies. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 1. Philadelphia, Pa: Lippincott-Raven; 1997:773-777.
34. Kuzniecky RI, Knowlton RC. Neuroimaging of epilepsy. Semin Neurol. 2002;22:279-288.
35. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62:S24-S29.
36. Asconape JJ, Penry JK. Poststroke seizures in the elderly. Clin Geriatr Med. 1991;7:483-492.
37. Ramsay RE, Rowan AJ, Pryor FM, Collins JF, 428 DSG. Treatment of seizures in the elderly: final analysis from the DVA Cooperative Study #428. Epilepsia. 2003;44:170 (Abstract).
38. Kilpatrick CJ, Davis SM, Tress BM, Rossiter SC, Hopper JL, Vandendriesen ML. Epileptic seizures in acute stroke. Arch Neurol. 1990;47:157-160.
39. Kotila M, Waltimo O. Epilepsy after stroke. Epilepsia. 1992;33:495-498.
40. De Carolis P, D'Alessandro R, Ferrara R, Andreoli A, Sacquegna T, Lugaresi E. Late seizures in patients with internal carotid and middle cerebral artery occlusive disease following ischaemic events. J Neurol Neurosurg Psychiatry. 1984;47:1345-1347.
41. Faught E, Peters D, Bartolucci A, Moore L, Miller PC. Seizures after primary intra-cerebral hemorrhage. Neurology. 1989;39:1089-1093.
42. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet. 2004;363:1184-1186.
43. Aminoff MJ, Parent JM. Comorbidity in adults. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 2. Philadelphia, Pa: Lippincott-Raven; 1997:1957-1970.
44. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20:791-803.
45. Williamson PD, Engel J Jr. Complex partial seizures. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 1. Philadelphia, Pa: Lippincott-Raven; 1997:557-566.
46. Siegel AM, Williamson PD. Parietal lobe epilepsy. Adv Neurol. 2000;84:189-199.
47. Adamolekun B, Jouny CC, Franaszczuk PJ, Bergey GK. Does antiepileptic drug withdrawal affect partial seizure duration? Epilepsia, 2004;45:58.
48. Williamson PD, Jobst BC. Frontal lobe epilepsy. Adv Neurol. 2000;84:215-242.
49. Laskowitz DT, Sperling MR, French JA, O'Connor MJ. The syndrome of frontal lobe epilepsy: characteristics and surgical management. Neurology. 1995;45:780-787.
50. Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia. 1998;39:1083-1087.
51. Van Sweden B, Wauquier A, Niedermeyer E. Normal aging and transient cognitive disorders in the elderly. In: Niedermeyer E, Lopes da Silva F, eds. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:340-348.
52. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003;2:404-409.
53. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;71 (suppl 2):S42-S48.
54. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology. 2003;60:555-559.
55. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63:S40-S48.
56. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 2004;5(suppl 1):S60-S65.
57. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol. 2003;54:75-85.
58. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1989;17:236-263.
59. Mayersohn MB. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, Wash: Applied Therapeutics, Inc; 1986:2-9.
60. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol. 1984;27:91-97.
61. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc. 1979;27:20-22.
62. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet. 1987;12:41-72.
63. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet. 1988;15:287-294.
64. Woodhouse KW, James OF. Hepatic drug metabolism and ageing. Br Med Bull. 1990;46:22-35.
65. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297-301.
66. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975;18:425-432.
67. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet. 1991;21:165-177.
68. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980;215:86-91.
69. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. J Pharm Sci. 1981;70:1104-1107.
70. Rowe JW, Andres R, Tobin JD, Morris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155-163.
71. Cloyd J. Commonly used antiepileptic drugs: age-related pharmacokinetics. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston, Mass: Butterworth-Heinemann; 1997:219-228,
72. Spina E. Carbamazepine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002.
73. Levy RH, Shen DD, Abbott FS, Riggs KW, Hachad H. Valproic acid: chemistry, biotransformation, and pharmacokinetics, In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002.
74. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther. 1982;31:301-304.
75. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
76. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokineiics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43:277-283.
77. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(suppl 6):13-18.
78. Henry DA, Lawson DH, Reavey P, Renfrew S. Hyponatraemia during carbamazepine treatment. Br Med J. 1977;1:83-84.
79. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18-S22.
80. Tartara A, Sartori I, Manni R, Galimberti CA, Di Fazio M, Perucca E. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurosci. 1996;17:429-432.
81. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37:539-543.
82. Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin Neuropharmacol. 1995;18:23-27.
83. Graves NM. Felbamate. Ann Pharmacother. 1993;27:1073-1081.
84. Anonymous. Acute liver failure linked to felbamate use. Am J Hosp Pharm. 1994;51:2882,2887.
85. O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology. 1996;46:1457-1459.
86. Richens A. Safety of lamotrigine. Epilepsia. 1994;35(suppl 5):S37-S40.
87. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia. 1993;34:163-165.
88. Schachter SC, Cramer GW, Thompson GD, Chaponis RJ, Mendelson MA, Lawhorne L. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc. 1998;46:1137-1141.
89. Birnbaum AK, Hardie NA, Conway JM, et al. Phenytoin use in elderly nursing home residents. Am J Geriatr Pharmacother. 2003;1:90-95.
90. Birnbaum AK, Hardie NA, Conway JM, et al. Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res. 2004;62:157-162.
91. Baker GA, Jacoby A, Buck D, Brooks J, Potts P, Chadwick DW. The quality of life of older people with epilepsy: findings from a UK community study. Seizure. 2001;10:92-99.
92. Bergey GK. Complex partial seizures: the clinicopathological spectrum. In: Bergey GK, ed. AAN Course Syllabus: Clinical Epilepsy I. St Paul, Minn: American Academy of Neurology; 2004.
93. Porter RJ, Meldrum BS. Overview: Antiepileptic Drugs. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 2. Philadelphia, Pa: Lippincott-Raven; 1997;1381-1382.
94. Kupferberg HJ, Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol. 2. Philadelphia, Pa: Lippincott-Raven; 1997:1417-1434.
95. Browne TR, Leduc B. Phenytoin and other hydantoins: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins;2002:565-580.
96. McLean MJ. Chemistry, absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York, NY: Raven Press; 1995.
97. Lunde PK, Rane A, Yaffe SJ, Lund L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther. 1970;11:846-855.
98. Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther. 1974;15:276-282.
99. Kober A, Olsson Y, Sjoholm I. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate. Mol Pharmacol. 1980;18:237-242.
100. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia. 1979;20:85-90.
101. Cato A 3rd, Gustavson LE, Qian J, El-Shourbagy T, Kelly EA. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia. 1998;39:43-47.
102. Sommerville JW, Collins SD. Tiagabine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002.
103. Anderson GD, Levy RH. Phenobarbital: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs. New York, NY: Raven Press; 1995:371-377.
104. Bottiger Y, Svensson JO, Stahle L. Lamotrigine drug interactions in a TDM material. Ther Drug Monit. 1999;21:171-174.
105. GlaxoSmithKline. Product information of lamictal (lamotrigine) tablets and lamictal (lamotrigine) chewable disposable tablets. In: Physician's Desk Reference. Montvale, NJ: Medical Economics; 1999:A143.
106. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42:535-541.
107. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy, retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-465.
108. Bialer M. Oxcarbazepine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:459-465.
109. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol. 1996;42:531-543.
110. Doose DR, Streeter AJ. Topiramate: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:727-734.
111. Blum RA, Comstpck TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56:154-159.
112. Patsalos PN. Levetiracetam: chemistry, biotransformation, pharmacokinetics, and drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins;2002:428-432.
113. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004;61:1-48.